Johnson & Johnsonvs.Zoetis
JNJ vs ZTS · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
Johnson & Johnson is about 19× larger than Zoetis by market cap; Zoetis trades at the lower P/E (12.4 vs 29.5); year to date, Johnson & Johnson leads (+24.2% vs −39.9%).
Side by side
| JNJ | ZTS | |
|---|---|---|
| Market cap | $620B | $32.9B |
| Price | $256.98 | $75.56 |
| Today | −0.8% | +0.6% |
| Return YTD | +24.2% | −39.9% |
| Return 1Y | +63.0% | −52.4% |
| P/E | 29.5 | 12.4 |
| P/S | 6.4 | 3.5 |
| P/B | 7.6 | 10.2 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Johnson & JohnsonJNJ
American healthcare group with a large pharmaceutical division (Innovative Medicine) and medtech division (MedTech).
Full JNJ profile →ZoetisZTS
The world’s largest animal health company — medicines and vaccines for pets and livestock, spun off from Pfizer in 2013.
Full ZTS profile →More comparisons in Big pharma
See where JNJ and ZTS sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →